DRTS Overview

Alpha Tau Medical Ltd is an Israel-based medical technology company that focuses on research, development and commercialization of Alpha DaRT Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) for the treatment of solid cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The Company has one subsidiary Healthcare Capital Corp.

Wall Street analysts forecast DRTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRTS is7.00 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Alpha Tau Medical Ltd revenue for the last quarter amounts to -11.00M USD, increased 29.43 % YoY.

Alpha Tau Medical Ltd. EPS for the last quarter amounts to -9120000.00 USD, increased 221.47 % YoY.

Alpha Tau Medical Ltd (DRTS) has 125 emplpoyees as of January 30 2026.

Today DRTS has the market capitalization of 608.00M USD.